Shenzhen Salubris Pharmaceuticals Co. Ltd. has disclosed new dual proprotein convertase subtilisin/kexin-type 9 (PCSK9) and lipoprotein(a) (Lp[a])-targeting agents potentially useful for the treatment of hypercholesterolemia.